Home Air Purification for Eosinophilic COPD
Primary Purpose
COPD, Eosinophilia
Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Air purifier
Sham air purifier
Sponsored by
About this trial
This is an interventional treatment trial for COPD
Eligibility Criteria
Inclusion Criteria:
- Age of 40 years or more
- Physician diagnosis of COPD [Global Initiative for Obstructive Lung Disease (GOLD) Stage II-IV disease with Forced Expiratory Volume (FEV1)/ Forced Vital Capacity (FVC) ≤70% and FEV1 (% predicted) <80%]
- Blood eosinophil count of >=150 cells per μL at screening or in the previous year
- Former smoker with tobacco exposure of >=10 pack-years
Exclusion Criteria:
- Inability to complete monthly questionnaires
- Inability to perform lung function testing
- Regularly using a portable HEPA air purifier in the home at time of enrollment
- End stage chronic disease with life expectancy <2 years as determined by PI judgment (e.g. under evaluation or listed for lung transplantation, malignancy, severe cirrhosis, severe heart failure)
- Living in location other than home (e.g. long term care facility)
- Planning to change residence within the study period
Sites / Locations
- Beth Israel Deaconess Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Sham Comparator
Experimental
Arm Label
Sham air purifier
True air purifier
Arm Description
Participants will receive a sham air purifier that will be installed in the bedroom and living room. These purifiers will make a noise, but will not filter the air.
Participants will receive a HEPA air purifier in the bedroom and living room.
Outcomes
Primary Outcome Measures
Change in forced expiratory volume in 1 second (FEV1)
FEV1 is the volume of air exhaled in the first second of a forced exhalation maneuver. Lower volumes indicate worse lung function.
Secondary Outcome Measures
Change in health status (also called health-related quality of life) by St. George Respiratory Questionnaire
The St. George's Respiratory Questionnaire is scored from 0 to 100. Higher scores indicate more health impairment.
Change in respiratory symptoms
The Breathlessness, Cough and Sputum Scale measures the severity of respiratory symptoms in COPD. The total score ranges from 0 to 12, with higher scores indicating greater symptom severity.
Change in functional capacity by 6 minute walk test
Baseline and 12 months post-intervention
Full Information
NCT ID
NCT04252235
First Posted
January 30, 2020
Last Updated
April 12, 2023
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
National Institute of Environmental Health Sciences (NIEHS)
1. Study Identification
Unique Protocol Identification Number
NCT04252235
Brief Title
Home Air Purification for Eosinophilic COPD
Official Title
A Randomized Controlled Trial of Home Air Purification for Eosinophilic COPD
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
March 15, 2021 (Actual)
Primary Completion Date
June 30, 2025 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center
Collaborators
National Institute of Environmental Health Sciences (NIEHS)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study evaluates the influence of home air purification on the lung health of adults with eosinophilic COPD. Half of the participants will receive real air purifiers (HEPA filters) and half will receive sham air purifiers.
Detailed Description
Chronic obstructive pulmonary disease (COPD) is the third most common cause of death in the United States, and is exacerbated by exposure to air pollution. Knowledge about whether air purification affects the health of those with eosinophilic COPD (approximately 40% of all COPD patients seeking care), who generally have more active airway inflammation. If found to be beneficial, home air purification may offer a non-pharmacologic intervention for a large proportion of people with this common and serious disease.
This study will evaluate whether home air purification affects lung function, respiratory symptoms, nasal biomarkers (inflammatory proteins and metals) among people with eosinophilic COPD. Participants will be randomized to receive real or sham air purifier in the bedroom and living room for 12 months. The intervention group will receive two high efficiency particulate air (HEPA) air purifiers, while the control group will receive two sham air purifiers that look and sound the same as real HEPA air purifiers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COPD, Eosinophilia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants will be randomized to receive real or sham HEPA filters in the bedroom and living room for a total of 12 months.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Sham air purifiers will be indistinguishable from real air purifiers. Only the research assistant installing the purifiers and the data coordinating center will have knowledge of assignment to real or sham purifiers.
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Sham air purifier
Arm Type
Sham Comparator
Arm Description
Participants will receive a sham air purifier that will be installed in the bedroom and living room. These purifiers will make a noise, but will not filter the air.
Arm Title
True air purifier
Arm Type
Experimental
Arm Description
Participants will receive a HEPA air purifier in the bedroom and living room.
Intervention Type
Device
Intervention Name(s)
Air purifier
Intervention Description
The intervention is the placement of active HEPA air purifiers in the bedroom and living room of the true air purifier arm. These air purifiers have been shown to reduce levels of particles in the home.
Intervention Type
Device
Intervention Name(s)
Sham air purifier
Intervention Description
The intervention is the placement of sham HEPA air purifiers in the bedroom and living room. These purifiers look identical to real HEPA air purifiers, but do not filter the air.
Primary Outcome Measure Information:
Title
Change in forced expiratory volume in 1 second (FEV1)
Description
FEV1 is the volume of air exhaled in the first second of a forced exhalation maneuver. Lower volumes indicate worse lung function.
Time Frame
Baseline [3 months before intervention and day of intervention] and post intervention [7 days, 6 months and 12 months]
Secondary Outcome Measure Information:
Title
Change in health status (also called health-related quality of life) by St. George Respiratory Questionnaire
Description
The St. George's Respiratory Questionnaire is scored from 0 to 100. Higher scores indicate more health impairment.
Time Frame
Baseline [3 months before intervention and day of intervention] and post-intervention [6 months and 12 months]
Title
Change in respiratory symptoms
Description
The Breathlessness, Cough and Sputum Scale measures the severity of respiratory symptoms in COPD. The total score ranges from 0 to 12, with higher scores indicating greater symptom severity.
Time Frame
Monthly for 3 months preintervention and 12 months post-intervention
Title
Change in functional capacity by 6 minute walk test
Description
Baseline and 12 months post-intervention
Time Frame
The 6 minute walk test measures distance (in meters) walked in a time of 6 minutes
Other Pre-specified Outcome Measures:
Title
Change in nasal inflammatory mediators
Description
Concentrations of inflammatory mediators relevant to allergic and non-allergic airway pathophysiology will be measured repeatedly at baseline and post-randomization in the nasal lining fluid by nasosorption. Mediators will include including Eotaxin, Eotaxin-3, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-8 (HA), IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, TARC, TNF-α, TNF-β, VEGF-A
Time Frame
Baseline [3 months before intervention and day of intervention] and post intervention [7 days, 6 months and 12 months]
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age of 40 years or more
Physician diagnosis of COPD [Global Initiative for Obstructive Lung Disease (GOLD) Stage II-IV disease with Forced Expiratory Volume (FEV1)/ Forced Vital Capacity (FVC) ≤70% and FEV1 (% predicted) <80%]
Blood eosinophil count of >=150 cells per μL at screening or in the previous year
Former smoker with tobacco exposure of >=10 pack-years
Exclusion Criteria:
Inability to complete monthly questionnaires
Inability to perform lung function testing
Regularly using a portable HEPA air purifier in the home at time of enrollment
End stage chronic disease with life expectancy <2 years as determined by PI judgment
Living in location other than home (e.g. long term care facility)
Planning to change residence within the study period
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mary B Rice, MD MPH
Organizational Affiliation
Beth Israel Deaconess Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
After study completion, data requests for post-hoc analyses may be submitted to the PI who will discuss each request with members of the research team and External Advisory Committee. If approved, we will facilitate secure access to data with appropriate coding files that will allow interpretation of the dataset. We will utilize data-sharing agreements to restrict the transfer of data, requiring that data be used only for research purposes. If excessive data preparation is needed, we will request funds from the requester to cover the additional personnel and resource costs.
IPD Sharing Time Frame
After study completion, requests for data sharing will be addressed within 3 months.
IPD Sharing Access Criteria
Data requests must be accompanied by a data analysis plan, which includes the scientific background and rationale for the proposed analysis, variables needed, analytical approach, and qualifications of the research team. Investigators must be able to demonstrate they have the skills and resources to analyze the data and protect the data in a secure environment.
Learn more about this trial
Home Air Purification for Eosinophilic COPD
We'll reach out to this number within 24 hrs